Abstract 4365908: A Novel Composite Artificial Intelligence-Electrocardiography Risk Score Is Independently Associated with Mortality in Chronic Tricuspid Regurgitation

A Andrea Ciobanu (University and Emergency Hospital, Bucharest, Romania) J Jwan Naser (Mayo Clinic, Rochester, Minnesota, United States) J Julia Wood (Mayo Clinic, Rochester, Minnesota, United States) P Paul Friedman (Mayo Clinic, Rochester, Minnesota, United States) D Dragos Vinereanu (Cardiology and Cardiovascular Surgery Department, University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital, Bucharest, Romania (D.V.).) V Vuyisile Nkomo (Mayo Clinic, Rochester, Minnesota, United States) C Cristina Pislaru (Mayo Clinic, Rochester, Minnesota, United States) K Kyla Lara-Breitinger (Mayo Clinic, Rochester, Minnesota, United States) J Jeremy Thaden (Mayo Clinic, Rochester, Minnesota, United States) P Patricia Pellikka (MAYO CLINIC COLLEGE MEDICINE, Rochester, Minnesota, United States) G Garvan Kane (Mayo Clinic, Rochester, Minnesota, United States) S Sorin Pislaru (Mayo Clinic, Rochester, Minnesota, United States) V Vidhu Anand (Mayo Clinic, Rochester, Minnesota, United States)

Abstract

Background: Tricuspid regurgitation (TR) is associated with significant morbidity, but individualized treatment and timing of intervention are yet to be defined. We previously proposed and validated artificial intelligence electrocardiography (AI-ECG) scores for various diseases. Whether incorporating AI-ECG information adds to risk stratification above and beyond classical clinical parameters is unknown. Objectives: To identify AI-ECG scores independently associated with all-cause mortality in chronic TR and to create a composite AI-ECG risk score. Methods: Patients with a first echocardiographic diagnosis of ≥moderate TR between 2005-2016 and an ECG within ±15 days were included. The Tricuspid Regurgitation Impact on Outcome (TRIO) score was calculated as previously described based on 8 simple parameters (age, sex, severe TR, heart failure, lung disease, heart rate, creatinine and AST). AI-ECG probabilities of low ejection fraction, aortic stenosis, amyloid, cirrhosis, atrial fibrillation and hypertrophic cardiomyopathy were estimated by existing algorithms; the first 4 were associated with all-cause mortality and a composite AI-ECG risk score was calculated (0-4; 1 point for each AI-ECG above specific threshold). Results: A total of 12,377 pts were included (age 72±13 yrs, 55% women). Over a median follow-up of 1.3 yrs (IQR 0.1 to 4.4), 7,121 pts (58%) died. Mortality risk increased significantly with higher composite AI-ECG risk score (Fig. 1A). On multivariable analysis (proportional hazards method), the composite AI-ECG risk score remained independently associated with death, even after adjusting for age, sex, high NT-proBNP levels (>2,500 pg/mL), right ventricular systolic pressure (RVSP), diuretic use and TRIO risk score category (Fig. 1B). Conclusions: Patients with ≥moderate TR show progressively worse survival with increasing composite AI-ECG risk score. Incorporating AI-derived information from a simple and inexpensive ECG may identify patients with the highest risk of mortality beyond clinical risk scores as TRIO or classical clinical, laboratory and echocardiographic parameters. Prospective validation of this approach needs to be tested in future trials.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (13)

A

Andrea Ciobanu

University and Emergency Hospital, Bucharest, Romania

J

Jwan Naser

Mayo Clinic, Rochester, Minnesota, United States

J

Julia Wood

Mayo Clinic, Rochester, Minnesota, United States

P

Paul Friedman

Mayo Clinic, Rochester, Minnesota, United States

D

Dragos Vinereanu

Cardiology and Cardiovascular Surgery Department, University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital, Bucharest, Romania (D.V.).

V

Vuyisile Nkomo

Mayo Clinic, Rochester, Minnesota, United States

C

Cristina Pislaru

Mayo Clinic, Rochester, Minnesota, United States

K

Kyla Lara-Breitinger

Mayo Clinic, Rochester, Minnesota, United States

J

Jeremy Thaden

Mayo Clinic, Rochester, Minnesota, United States

P

Patricia Pellikka

MAYO CLINIC COLLEGE MEDICINE, Rochester, Minnesota, United States

G

Garvan Kane

Mayo Clinic, Rochester, Minnesota, United States

S

Sorin Pislaru

Mayo Clinic, Rochester, Minnesota, United States

V

Vidhu Anand

Mayo Clinic, Rochester, Minnesota, United States